甲基受体2是一种潜在的生物标志物和炎症性肠道疾病的治疗标
Wen-Sheng Yang1, Xiao-Zhen Wang2, Wei Wu1
1Department of Clinical Pharmacy, Children's Hospital of Fudan University, National Children's Medical Center, Shanghai, 201102, China.
Acta pharmacologica Sinica
|November 3, 2025
概括
甲基受体2 (FPR2/ALX) 在炎症性肠病 (IBD) 中表达高,并预测治疗反应不佳. 调节FPR2/ALX在IBD的临床前模型中显示出治疗潜力.
科学领域:
- 胃肠病学 胃肠病学
- 免疫学 免疫学 免疫学
- 分子生物学分子生物学
背景情况:
- 炎症性肠病 (IBD),包括性结肠炎 (UC) 和克罗恩病 (CD),面临着有限的治疗选择和治疗上限的挑战.
- 无法解决炎症是IBD进展的主要驱动因素.
- 甲基受体2 (FPR2/ALX) 是炎症解消的关键媒介,也是潜在的治疗点.
研究的目的:
- 研究FPR2/ALX表达模式和在活跃IBD患者的髓状和淋巴状细胞中的临床相关性.
- 在大肠炎的临床前模型中评估FPR2/ALX调节器的治疗潜力.
主要方法:
- 来自GEO数据库对IBD患者样本的转录和单细胞RNA测序数据的分析.
- 在野生类型和Fpr2沉默小鼠中使用硫酸 (DSS) 诱导的结肠炎模型.
- 通过口服服用FPR2/ALX调节剂昆-C1 (QC1) 和昆-C7 (QC7).
主要成果:
- 在IBD患者的结肠粘膜中观察到异常的FPR2/ALX表达和相关基因.
- 高粘膜FPR2/ALX水平与改变的MAPK通路和髓状细胞组成相关,并预测对抗TNF-α治疗 (infliximab) 的反应不佳.
- 口服QC1或QC7治疗显著降低了野生类型小鼠的疾病活性,Fpr2沉默小鼠的效果受损.
结论:
- 在IBD中,FPR2/ALX被上调,并与疾病严重程度和治疗反应有关.
- 在临床前结肠炎模型中,FPR2/ALX调制证明了治疗疗效.
- FPR2/ALX代表了炎症性肠病的潜在生物标志物和治疗标.
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
476
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
476
Inflammatory Bowel Disease IV: Pharmacological Management
463
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
463
Inflammatory Bowel Disease II: Crohn's Disease
943
Introduction
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
943
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
475
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
475
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
626
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
626


